

# **Human Tumor Necrosis Factor-Alpha (TNF-a, Mutant)**

### ORDERING INFORMATION

Catalog No: rAP-0158; Size: 10 µg; 50 µg Storage: <- 20° C

# Synonyms:

TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, Cachectin, DIF, TNFA, TNFSF2.

#### Introduction:

The clinical use of the potent anti-tumor activity of TNF-a has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-α, which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines *in vitro*, and exhibited lower systemic toxicity *in vivo*.

Recombinant Human TNF-a Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven tohave more activity and with less inflammatory side effect *in vivo*.

### **Description:**

Tumor Necrosis Factor-a Variant Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16598 Dalton. The TNF-alpha Variant is purified by standard chromatographic techniques.

### Source:

Escherichia Coli.

# **Physical Appearance:**

Sterile Filtered White lyophilized (freeze-dried) powder.

#### Formulation:

The protein was lyophilized after extensive dialysis against 0.5x PBS pH -7.

### Solubility:

It is recommended to reconstitute the lyophilized Tumor Necrosis Factor-alpha Variant in sterile  $18M\Omega$ -cm H2O not less than  $100\mu g/ml$ , which can then be further diluted to other agueous solutions.

#### Stability:

Lyophilized Tumor Necrosis Factor-a Variant although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution TNF-a Variant should be stored at 4°C between 2-7 days and for future use below -18°C.

For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Please prevent freeze-thaw cycles.

#### **Purity:**

Greater than 95.0% as determined by:

- (a) Analysis by RP-HPLC.
- (b) Analysis by SDS-PAGE.

Contact & Ordering Information: Angio-Proteomie, 11 Park Drive, Suite 12, Boston, MA 02215, USA. Fax: (480) 247-4337, angioproteomie@gmail.com



### Amino acid sequence:

M<u>RKR</u>KPVAHV VÅNPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA<u>F</u>

# **Biological Activity:**

The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is < 0.05ng/ml, corresponding to a Specific Activity of 1 x 10<sup>8</sup> IU/mg

### Usage:

Angio-Proteomie's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.